T1	Condition 289 310	anaphylactic reaction
T2	Condition-Name 289 310	anaphylactic reaction
E1	Condition:T1 Name:T2
T3	Condition 350 368	autoimmune disease
T4	Condition-Name 350 368	autoimmune disease
E3	Condition:T3 Name:T4 Temporality:E24 Severity:T48
T5	Procedure 478 503	immunosuppressive therapy
T6	Procedure-Name 478 503	immunosuppressive therapy
E5	Procedure:T5 Name:T6 Temporality:E27
T7	Eq-Operator 460 461	≥
A1	Eq-Operator-Value T7 GTEQ
T8	Eq-Operator 525 526	>
A2	Eq-Operator-Value T8 GT
T9	Eq-Operator 551 552	>
A3	Eq-Operator-Value T9 GT
T10	Eq-Temporal-Unit 188 194	months
A4	Eq-Temporal-Unit-Value T10 month
T11	Eq-Value 186 187	3
T12	Eq-Value 462 463	3
T13	Eq-Value 526 528	10
T14	Eq-Value 552 555	1.5
T15	Eq-Comparison 460 463	≥ 3
E6	Eq-Comparison:T15 Operator:T7 Value:T12
T16	Eq-Comparison 525 535	>10 mg/day
E7	Eq-Comparison:T16 Operator:T8 Value:T13 Unit:T57 Per:T58
T17	Eq-Comparison 551 562	>1.5 mg/day
E8	Eq-Comparison:T17 Operator:T9 Value:T14 Unit:T59 Per:T60
T18	Procedure 39 48	treatment
E2	Procedure:T18 Temporality:E4
T19	Eq-Comparison 25 35	Initiation
E4	Eq-Comparison:T19 Temporal-Recency:T20
T20	Eq-Temporal-Recency 25 35	Initiation
A5	Eq-Temporal-Recency-Value T20 first-time
T21	Procedure 63 66	ICI
E9	Procedure:T21 Name:T22 Minimum-Count:E10
T22	Procedure-Name 63 66	ICI
T23	Eq-Comparison 56 62	single
E10	Eq-Comparison:T23 Value:T24
T24	Eq-Value 56 62	single
T25	Procedure 87 91	ICIs
E11	Procedure:T25 Name:T26 Minimum-Count:E12
T26	Procedure-Name 87 91	ICIs
T27	Eq-Comparison 72 83	combination
E12	Eq-Comparison:T27 Operator:T28
T28	Eq-Operator 72 83	combination
A6	Eq-Operator-Value T28 GT
T29	Or 67 69	or
E13	Or:T29 Arg:E9 Arg2:E11
R1	Using Arg1:E2 Arg2:E9	
R2	Using Arg1:E2 Arg2:E11	
T30	Observation 159 174	Life expectancy
E14	Observation:T30 Name:T31 Eq-Comparison:E15
T31	Observation-Name 159 174	Life expectancy
T32	Eq-Comparison 175 194	lower than 3 months
E15	Eq-Comparison:T32 Operator:T33 Value:T11 Temporal-Unit:T10
T33	Eq-Operator 175 185	lower than
A7	Eq-Operator-Value T33 LT
T34	Procedure 218 227	treatment
E16	Procedure:T34 Temporality:E18
T35	Procedure 233 237	ICIs
E17	Procedure:T35 Name:T36
T36	Procedure-Name 233 237	ICIs
R3	Using Arg1:E16 Arg2:E17	
T37	Eq-Comparison 204 214	initiation
E18	Eq-Comparison:T37 Temporal-Recency:T38
T38	Eq-Temporal-Recency 204 214	initiation
A8	Eq-Temporal-Recency-Value T38 first-time
T39	Temporal-Connection 195 199	from
E19	Temporal-Connection:T39 Arg:E15 Arg2:E18
A9	Temporal-Connection-Type-Value E19 after
T40	Condition 251 267	hypersensitivity
E20	Condition:T40 Name:T42
T41	Allergy 280 288	allergic
E21	Allergy:T41 Name:E22
T42	Condition-Name 251 267	hypersensitivity
T43	Procedure 333 336	ICI
E22	Procedure:T43 Name:T44
T44	Procedure-Name 333 336	ICI
T45	Or 268 270	or
E23	Or:T45 Arg:E20 Arg2:E21
R4	Caused-By Arg1:E20 Arg2:E22	
R5	Caused-By Arg1:E1 Arg2:E22	
T46	Eq-Comparison 343 349	Active
E24	Eq-Comparison:T46 Temporal-Period:T47
T47	Eq-Temporal-Period 343 349	Active
A10	Eq-Temporal-Period-Value T47 present
T48	Severity 374 380	severe
A11	Severity-Value T48 severe
T49	Observation 399 433	Eastern Cooperative Oncology Group
E25	Observation:T49 Name:T50
T50	Observation-Name 399 433	Eastern Cooperative Oncology Group
A12	Observation-Type-Value T50 clinical-score
T51	Observation 435 439	ECOG
E26	Observation:T51 Name:T52 Eq-Comparison:E6
T52	Observation-Name 435 439	ECOG
A13	Observation-Type-Value T52 clinical-score
R6	Abbrev-Of Arg1:E26 Arg2:E25	
T53	Eq-Comparison 470 477	Ongoing
E27	Eq-Comparison:T53 Temporal-Period:T54
T54	Eq-Temporal-Period 470 477	Ongoing
A14	Eq-Temporal-Period-Value T54 present
T55	Drug 505 515	prednisone
E28	Drug:T55 Name:T56 Dose:E7
T56	Drug-Name 505 515	prednisone
T57	Eq-Unit 529 531	mg
T58	Eq-Temporal-Unit 532 535	day
A15	Eq-Temporal-Unit-Value T58 day
T59	Eq-Unit 556 558	mg
T60	Eq-Temporal-Unit 559 562	day
A16	Eq-Temporal-Unit-Value T60 day
T61	Drug 566 579	dexamethasone
E29	Drug:T61 Name:T62 Dose:E8
T62	Drug-Name 566 579	dexamethasone
R7	Equivalent-To Arg1:E29 Arg2:E28	
T63	Drug 601 613	azathioprine
E30	Drug:T63 Name:T64
T64	Drug-Name 601 613	azathioprine
T65	Or 582 588	and/or
E31	Or:T65 Arg:E28 Arg2:E30
T66	Drug 615 627	methotrexate
E32	Drug:T66 Name:T67
T67	Drug-Name 615 627	methotrexate
T68	Drug 629 642	mycophenolate
E33	Drug:T68 Name:T69
T69	Drug-Name 629 642	mycophenolate
T70	Drug 644 660	cyclophosphamide
E34	Drug:T70 Name:T71
T71	Drug-Name 644 660	cyclophosphamide
T72	Drug 662 673	leflunomide
E35	Drug:T72 Name:T73
T73	Drug-Name 662 673	leflunomide
T74	Drug 675 684	rituximab
E36	Drug:T74 Name:T75
T75	Drug-Name 675 684	rituximab
T76	Drug 686 718	anti-tumor necrosis factor drugs
E37	Drug:T76 Name:T77
T77	Drug-Name 686 718	anti-tumor necrosis factor drugs
T78	Drug 720 730	infliximab
E38	Drug:T78 Name:T79
T79	Drug-Name 720 730	infliximab
T80	Drug 732 742	etanercept
E39	Drug:T80 Name:T81
T81	Drug-Name 732 742	etanercept
T82	Drug 744 754	adalimumab
E40	Drug:T82 Name:T83
T83	Drug-Name 744 754	adalimumab
T84	Drug 756 765	golimumab
E41	Drug:T84 Name:T85
T85	Drug-Name 756 765	golimumab
R8	Example-Of Arg1:E38 Arg2:E37	
R9	Example-Of Arg1:E39 Arg2:E37	
R10	Example-Of Arg1:E40 Arg2:E37	
R11	Example-Of Arg1:E41 Arg2:E37	
T86	Drug 768 777	belimumab
E42	Drug:T86 Name:T87
T87	Drug-Name 768 777	belimumab
T88	Drug 782 791	abatacept
E43	Drug:T88 Name:T89
T89	Drug-Name 782 791	abatacept
T90	Or 778 781	and
E44	Or:T90 Arg:E42 Arg2:E43
